Adaptimmune Therapeutics PLC
NASDAQ:ADAP
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. The company is headquartered in Abingdon, Oxfordshire and currently employs 494 full-time employees. The company went IPO on 2015-05-06. The Company’s Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. The Company’s clinical trials include SPEARHEAD-1 Phase II Trial with afamitresgene autoleucel (afami-cel), SPEARHEAD-2 Phase II trial with afami-cel, SURPASS Phase I trial with ADP-A2M4CD8, ADP-A2AFP Phase I trial and Afami-cel Phase I trial radiation sub-study.
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. The company is headquartered in Abingdon, Oxfordshire and currently employs 494 full-time employees. The company went IPO on 2015-05-06. The Company’s Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. The Company’s clinical trials include SPEARHEAD-1 Phase II Trial with afamitresgene autoleucel (afami-cel), SPEARHEAD-2 Phase II trial with afami-cel, SURPASS Phase I trial with ADP-A2M4CD8, ADP-A2AFP Phase I trial and Afami-cel Phase I trial radiation sub-study.
Revenue Guidance: Adaptimmune issued its first annual TECELRA sales guidance, targeting $35 million to $45 million for 2025.
Q1 Sales: TECELRA generated net sales of $4 million in its first full quarter on the market.
Launch Momentum: The TECELRA launch is progressing faster than anticipated, with 28 treatment centers already accepting referrals and full network activation expected by year-end—one year ahead of plan.
Manufacturing Performance: Manufacturing success rate remains at 100% with no capacity constraints and an average turnaround of 27 days, ahead of the 30-day target.
Gross Margin: Q1 gross margin was approximately 78%, higher than the anticipated long-term average of 70%.
No Patient Denials: All patients seeking TECELRA have had payer coverage, with no denials reported to date.
Cash Position: Substantial doubt about the company’s ability to continue as a going concern remains, and cash runway is less than 12 months.
Lete-cel Progress: Launch readiness for lete-cel is on track, with rolling BLA initiation expected before year-end and anticipated approval in 2026.
